Opinion|Videos|December 22, 2023

How Do These Data Apply to Community Oncologists?

Author(s)Danai Dima, MD

Explanation of how these data apply to community oncologists.

Episodes in this series

Danai Dima, MD, an expert on multiple myeloma

EP. 1 Overview of Teclistamab and its MOA in R/R MM

Danai Dima, MD, an expert on multiple myeloma

EP. 2 Patient Characteristics in Real-World Study on Teclistamab

Danai Dima, MD, an expert on multiple myeloma

EP. 3 The Real-World Effectiveness of Treatment with Teclistamab for Patients with R/R MM

Danai Dima, MD, an expert on multiple myeloma

EP. 4 The Efficacy and Safety data and the Potential Impact on Treatment Guidelines and Practice

Danai Dima, MD, an expert on multiple myeloma

EP. 5 How Do These Data Apply to Community Oncologists?

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma

November 12th, 2026

Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma

During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.

Trending on Targeted Onc

Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC

Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma

FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL

DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC

New ACS Guidelines Push for Earlier Prostate Cancer Screening